GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GlaxoSmithKline (GSK) has announced a new clinical study titled ‘A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)’. The study aims to assess the effectiveness and safety of belantamab mafodotin, administered on an extended schedule, in combination with other cancer treatments for patients with relapsed-refractory multiple myeloma. The primary goal is to determine if this approach can effectively treat the cancer while reducing side effects, particularly those affecting the eyes.
The study is testing three experimental combinations of drugs: Belantamab mafodotin with Pomalidomide and Dexamethasone (BPd), Belantamab mafodotin with Bortezomib and Dexamethasone (BVd), and Belantamab mafodotin with Carfilzomib and Dexamethasone (BKd). These combinations aim to enhance treatment efficacy while minimizing adverse effects.
This interventional study is designed as a Phase 2, open-label, non-randomized trial with a parallel intervention model. There is no masking involved, and the primary purpose is treatment-focused, which allows for a direct assessment of the drug combinations’ impact on the disease.
The study is set to begin on November 10, 2025, which is also the date of the last update. The primary completion and estimated overall completion dates have not been specified yet. These dates are crucial as they mark the timeline for data collection and analysis, which will influence the study’s findings and subsequent regulatory decisions.
The announcement of this study could potentially impact GSK’s stock performance positively, as successful results may strengthen their position in the oncology market. Investors will be keenly watching for updates, especially given the competitive landscape in multiple myeloma treatments, where advancements can lead to significant market shifts.
The study is currently not yet recruiting, and further details can be accessed on the ClinicalTrials portal.
To learn more about GSK’s potential, visit the GlaxoSmithKline drug pipeline page.